AMMF’s Virtual 2021 European Cholangiocarcinoma Conference

Poster Presentations 2021

1. Sarah Koushyar, Cardiff University

Wnt signalling regulates metastatic cholangiocarcinoma Read more

2. Colm O’Rourke, University of Copenhagen, Denmark

Whole-transcriptome profiling of biopsies from advanced intrahepatic cholangiocarcinoma (iCCA) reveals a prognostic signature with treatment implications Read more

3. Mireia Sueca-Comes, University of Nottingham

The role of mesenchymal cells in cholangiocarcinoma Read more

4. Vera Cappelletti, Fondazione IRCCS Istituto Nazionale, Milan, Italy

Liquid biopsy is feasible in biliary tract cancer patients and opens new perspectives Read more

5. Pedro Rodrigues, Donostia University Hospital/CIBERehd Instituto de Salud Carlos III, San Sebastian, Spain

KLF5 upregulation is a common event in cholangiocarcinoma, acting as an oncogene and constituting a bad prognostic factor Read more

 6. Pietro Carotenuto, TIGEM – Telethon Institute of Genetics and Medicine, Pozzuoli, Italy

Integrative analysis of the genomic and transcriptomic landscape identifies novel key genes as a therapeutic target in bile duct cancer Read more

7. Richard Syms, Imperial College London

T2 mapping of cholangiocarcinoma using internal coilsRead more

8. Eirini Konstantinidou, Beth Israel Deaconess Medical Center, Boston, USA

Hypercalcaemia in advanced cholangiocarcinomaRead more

9. Stephanie Roessler, University Hospital Heidelberg, Germany

Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal papillary and tubulopapillary cholangiocarcinogenesis Read more

10.  Do-Youn Oh, Seoul National University College of Medicine, Korea

Zanidatamab, a novel human epidermal growth factor receptor 2 (HER2)-targeted antibody, in HER2-expressing biliary tract cancer: results from a Ph 1 study (ZW25 101) and design of a Ph 2b study, HERIZON-BTC-01 Read more

11. Antoine Hollebecque, Gustave Roussy, Villejuif, France

Efficacy and safety of pemigatinib in European patients with previously treated locally advanced or metastatic cholangiocarcinoma: a FIGHT-202 subgroup analysis Read more

12.  Serena Mancarella, National Institute of Gastroenterology, Castellana Grotte, Italy

Crenigacestat inhibits iCCA tumour progression via Notch1/HES1/CD90 pathway Read more

13.  Georgina Morris, University of Manchester

Identification of patients with intrahepatic cholangiocarcinoma (iCCA) presenting as cancer of unknown primary (CUP) Read more

14. Isioma Egbuniwe, University of Nottingham

Prognostic value of tumour-infiltrating CD68+ macrophages is dependent upon location within cholangiocarcinoma tumours Read more

15. Julien Edeline, Centre Eugène Marquis, Rennes, France

Systemic review and pooled analysis of locoregional therapies in patients with intrahepatic cholangiocarcinoma Read more

16. Silve Vicente, University of Navarra, Spain

FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted Read more

17. Waleed Ali, Albert Einstein College of Medicine, New York, USA

An in silico analysis of differentially expressed genes and their prognostic utility in Cholangiocarcinoma Read more


Back to previous page